Listicle

Listicle: Maximising outsourcing models beyond time and cost

28 September 2022

Challenges in outsourcing drug discovery In this listicle, SAMDITech outlines the benefits of outsourcing models in the pharmaceutical industry, looking past perceived costs to the value outsourcing can bring.   The goal of drug discovery is clear: Identify the most promising leads in the shortest amount of time. Many companies have several projects ongoing simultaneously, […]

Listicle: Selecting the best gene delivery method

7 June 2022

 Mirus Bio outlines when to use transfection reagents, viral transduction or electroporation   No single delivery method is ideal for all situations, but researchers may routinely employ a suboptimal approach for the sake of familiarity or to avoid any start-up costs associated with new methods.   The uses of nucleic acid delivery have expanded from recombinant […]

Listicle: Driving production in biologics with automation 

4 May 2022

Drug development technology has evolved rapidly in recent years, and with the industry advancement comes an increased capability of producing high-quality targeted large molecule drugs such as biologics and biosimilars. The significance of biologics is far-reaching, including treatment of rheumatologic diseases, cancer, diabetes and anaemia. The range of therapy modalities is ever-expanding and at present […]

Listicle: Lithuania’s biotechnology growth strategy

3 March 2022

Lithuania is dedicating time and resources establishing itself as a life science and biotechnology hub of excellence. DDW’s Megan Thomas analyses four pillars of Lithuania’s growth strategy, which involves ensuring female scientists take leading roles in industry, focusing on investment, developing a strong talent pool as well establishing itself as a go-to destination for clinical trials. […]

Listicle: Experts on the differences between FDA and EMA regulations

6 October 2021

Biotechs involved in drug discovery have to navigate increasingly complex regulatory environments across borders. Experienced experts and non-executive advisors to Arriello, Eric Caugant, Principal Consultant at Pharmacovigilance Systems Consulting & Board advisor to Arriello, and Judi Sills, JM Sills Consulting & Board advisor to Arriello, highlight the main differences between US and EU requirements, and advise on […]